Sign up
Log in
Goldman Sachs Maintains Buy on Biogen, Lowers Price Target to $197
Share
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $219 to $197.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2025 Webull. All Rights Reserved